Clinical Intelligence
search
TinyFish Clinical Research
Autonomous agentic retrieval of clinical trials, methodologies, and therapeutic leads.
NCT0421239Clinical Trial98% Match
Targeted KRAS G12C Inhibition in Advanced NSCLC
TinyFish identified this Phase III, randomized, double-blind study evaluating the efficacy and safety of covalent inhibitors targeting the specific KRAS G12C mutation found in Patient PT-8829-A.
sourceSource: ClinicalTrials.gov
biotechTarget: KRAS G12C
updateExtracted: 2 hrs ago
Relevance Score
98/ 100
Methodology LeadResearch Paper85% Match
Novel Allosteric Binding Sites in TP53 Mutants
Extracted from an un-indexed pharma portal. This methodology describes a new approach to targeting TP53 R273H mutations using allosteric modulators, highly relevant to Patient PT-8829-A's secondary mutation profile.
sourceSource: Un-indexed Portal
biotechTarget: TP53 R273H
updateExtracted: 5 hrs ago
Relevance Score
85/ 100